<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TOLAZAMIDE</span><br/>(tole-az'a-mide)<br/><span class="topboxtradename">Tolinase<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">sulfonylurea antidiabetic</span><br/><b>Prototype: </b>Glyburide<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 250 mg, 500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Orally effective sulfonylurea hypoglycemic structurally and pharmacologically related to tolbutamide but about 5 times more
         potent. Lowers blood glucose primarily by stimulating pancreatic beta cells to secrete insulin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antidiabetic action is a result of stimulation of the pancreas to secrete more insulin in the presence of blood sugar. As
         with other sulfonylureas, ineffective in the absence of functioning beta cells.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Mild to moderately severe type 2 diabetes mellitus that cannot be controlled by diet and weight reduction and that is uncomplicated
         by acidosis, ketosis, coma. Effective in primary or secondary failures to other sulfonylurea
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known sensitivity to sulfonylureas and to sulfonamides; type 1 diabetes complicated by ketoacidosis; infection; trauma; pregnancy
         (category C). Safety in lactation or children is not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Type 2 Diabetes Mellitus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg1 g q.d. to b.i.d. a.c., may adjust dose by 100250 mg/d at weekly intervals (max: 1 g/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give in the morning with or before meals.</li>
<li>Divide dose of more than 500 mg and give b.i.d.</li>
<li>Crush tablet if patient is unable to swallow it whole. Be sure to give with an allowable fluid, not dry.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container unless otherwise directed. Keep
            drug out of the reach of children.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span> Nausea, vomiting, cholestatic jaundice. <span class="typehead">Metabolic:</span> Hypoglycemia. <span class="typehead">CNS:</span> Vertigo. <span class="typehead">Skin:</span> Photosensitivity. <span class="typehead">Hematologic:</span> Agranulocytosis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> elicits disulfiram-type reaction in some patients; <span class="classification">oral anticoagulants</span>, <b>chloramphenicol,</b> <b>clofibrate,</b> <b>phenylbutazone,</b> <span class="classification">mao inhibitors</span>, <span class="classification">salicylates</span>, <b>probenecid,</b> <span class="classification">sulfonamides</span> may potentiate hypoglycemic actions; <span class="classification">thiazides</span> may antagonize hypoglycemic effects; <b>cimetidine</b> may increase tolazamide levels, causing hypoglycemia. <span class="typehead">Herbal:</span> <b>Garlic,</b> <b>ginseng</b> may potentiate hypoglycemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from GI tract. <span class="typehead">Onset:</span> 60 min. <span class="typehead">Peak:</span> 46 h. <span class="typehead">Duration:</span> 1015 h (up to 20 h in some patients). <span class="typehead">Distribution:</span> Distributed in highest concentrations in liver, kidneys, and intestines; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized extensively in liver. <span class="typehead">Elimination:</span> 85% excreted in urine, 15% in feces. <span class="typehead">Half-Life:</span> 7 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Be aware that reduction of dose frequently alleviates most mild to moderately severe hypoglycemic symptoms.</li>
<li>Observe patients with a history of ketoacidosis or coma closely, especially during the early adjustment period.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Check blood glucose and urine daily for sugar and acetone. Important to continue close medical supervision for first 6 wk
            of treatment.
         </li>
<li>Be aware that doses &gt;1000 mg/d rarely provide improvement in diabetic control.</li>
<li>Do not take OTC preparations unless approved or prescribed by physician.</li>
<li>Understand that alcohol can precipitate a disulfiram-type reaction.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>